Background and Objectives: The most common adverse events (AEs) after alemtuzumab (ALZ) include adverse infusion reactions, infections, and autoimmune disorders. Skin AEs are common during infusion, but there are few reported cases of long-term skin autoimmune disease. Methods: A retrospective case series of patients developing long-term autoimmune skin disorders after ALZ administration in a tertiary care hospital. Results: Of 133 patients treated with ALZ, 8 patients (6.02%) developed 9 autoimmune cutaneous AEs, including 4 events of alopecia areata, 2 of vitiligo, 2 of chronic urticaria, and 1 of inflammatory atrichia. Three of them occurred between the first and the second infusion. Discussion: The lesions described are secondary to autoimmune disorders, probably related to immune dysregulation because of a differential lymphocyte repopulation after ALZ. Autoimmune cutaneous AEs may be frequent, and it would be recommended to monitor its appearance to treat them.
Background and Objectives: The most common adverse events (AEs) after alemtuzumab (ALZ) include adverse infusion reactions, infections, and autoimmune disorders. Skin AEs are common during infusion, but there are few reported cases of long-term skin autoimmune disease. Methods: A retrospective case series of patients developing long-term autoimmune skin disorders after ALZ administration in a tertiary care hospital. Results: Of 133 patients treated with ALZ, 8 patients (6.02%) developed 9 autoimmune cutaneous AEs, including 4 events of alopecia areata, 2 of vitiligo, 2 of chronic urticaria, and 1 of inflammatory atrichia. Three of them occurred between the first and the second infusion. Discussion: The lesions described are secondary to autoimmune disorders, probably related to immune dysregulation because of a differential lymphocyte repopulation after ALZ. Autoimmune cutaneous AEs may be frequent, and it would be recommended to monitor its appearance to treat them.
Authors: Adam Cuker; Alasdair J Coles; Herman Sullivan; Edward Fox; Mark Goldberg; Pedro Oyuela; Annie Purvis; Diana S Beardsley; David H Margolin Journal: Blood Date: 2011-09-29 Impact factor: 22.113
Authors: Benoit Meunier; Audrey Rico; Julie Seguier; Clemence Boutiere; Mikael Ebbo; Jean Robert Harle; Nicolas Schleinitz; Jean Pelletier Journal: Mult Scler Date: 2018-01-23 Impact factor: 6.312
Authors: Maria di Ioia; Deborah Farina; Valeria di Tommaso; Daniela Travaglini; Erika Pietrolongo; Marco Onofrj; Giovanna de Luca Journal: Mult Scler Date: 2018-01-23 Impact factor: 6.312
Authors: Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston Journal: Lancet Date: 2012-11-01 Impact factor: 79.321
Authors: Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston Journal: Lancet Date: 2012-11-01 Impact factor: 79.321
Authors: Yanping Hu; Michael J Turner; Jacqueline Shields; Matthew S Gale; Elizabeth Hutto; Bruce L Roberts; William M Siders; Johanne M Kaplan Journal: Immunology Date: 2009-10 Impact factor: 7.397
Authors: Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles Journal: J Clin Invest Date: 2009-06-22 Impact factor: 14.808
Authors: Orla Tuohy; Lisa Costelloe; Grant Hill-Cawthorne; Ingunn Bjornson; Katharine Harding; Neil Robertson; Karen May; Tom Button; Laura Azzopardi; Onajite Kousin-Ezewu; Michael T Fahey; Joanne Jones; D Alastair S Compston; Alasdair Coles Journal: J Neurol Neurosurg Psychiatry Date: 2014-05-21 Impact factor: 10.154